Remed리메드
302550 · KOSDAQ · ₩302550 · 리메드
₩2,215▼ ₩80 (3.49%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 56.3% | 57.5% | 55.5% | 48.7% | 52.4% | 51.5% |
| Operating margin | 7.2% | 3.0% | 4.4% | −15.4% | 7.8% | 5.6% |
| Net margin | 7.6% | 2.1% | 28.1% | 4.3% | 18.7% | 3.7% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +10.4% | −4.1% | +37.9% | −13.2% | +5.8% | — |
| Operating income growth | +169.1% | −35.3% | +139.2% | −272.2% | +47.9% | — |
| Net income growth | +289.6% | −92.7% | +799.7% | −80.1% | +431.7% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 5.2% | 1.3% | 20.2% | 2.6% | 14.3% | 2.9% |
| Return on assets | 0.8% | −0.1% | 12.9% | 0.5% | 5.1% | 1.0% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 44.7% | 36.6% | 46.7% | 78.8% | 160.4% | 195.8% |
| Net debt to equity | −20.3% | −18.6% | −10.3% | −14.6% | 64.5% | 64.0% |
| Current ratio | 233.9% | 293.2% | 317.0% | 131.1% | 97.2% | 889.7% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Remed / 리메드 / 302550 / KRX:302550
Source: KRX statistical information